Patents Assigned to Avicenna Research Institute
  • DIAGNOSTIC AND THERAPEUTIC TARGET
    Publication number: 20140161809
    Abstract: An in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells from said subject, wherein an increased expression level of PRELP, as compared to healthy donors, indicates an increased probability of said subject suffering from cancer. The disclosure further relates to antibodies specific for PRELP and their use in diagnosis and therapy as well as a method for indicating a cell as a cancer cell.
    Type: Application
    Filed: January 30, 2014
    Publication date: June 12, 2014
    Applicant: Avicenna Research Institute
    Inventor: Hodjattallah Rabbani
  • Diagnostic and therapeutic target
    Patent number: 8658380
    Abstract: The present invention relates to an in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells from said subject, wherein an increased expression level of PRELP, as compared to healthy donors, indicates an increased probability of said subject suffering from cancer. It further relates to antibodies specific for PRELP and their use in diagnosis and therapy as well as a method for indicating a cell as a cancer cell.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: February 25, 2014
    Assignee: Avicenna Research Institute
    Inventor: Hodjattallah Rabbani